These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

354 related items for PubMed ID: 28960321

  • 1. How do I … manage the platelet transfusion-refractory patient?
    Juskewitch JE, Norgan AP, De Goey SR, Duellman PM, Wakefield LL, Gandhi MJ, Stubbs JR, Kreuter JD.
    Transfusion; 2017 Dec; 57(12):2828-2835. PubMed ID: 28960321
    [Abstract] [Full Text] [Related]

  • 2. Analysis of platelet-reactive alloantibodies and evaluation of cross-match-compatible platelets for the management of patients with transfusion refractoriness.
    Wang J, Xia W, Deng J, Xu X, Shao Y, Ding H, Chen Y, Liu J, Chen D, Ye X, Santoso S.
    Transfus Med; 2018 Feb; 28(1):40-46. PubMed ID: 28516675
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Management of patients with hematologic malignancies and aplastic anemia who are refractory to platelet transfusions.
    Sandler SG.
    Haematologia (Budap); 1998 Feb; 29(1):1-11. PubMed ID: 9704252
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Prevalence of platelet-specific antibodies and efficacy of crossmatch-compatible platelet transfusions in refractory patients.
    Jia Y, Li W, Liu N, Zhang K, Gong Z, Li D, Wang L, Wang D, Jing Y, Wang J, Shan X.
    Transfus Med; 2014 Dec; 24(6):406-10. PubMed ID: 25327352
    [Abstract] [Full Text] [Related]

  • 7. Management of the Platelet Refractory Patient.
    Forest SK, Hod EA.
    Hematol Oncol Clin North Am; 2016 Jun; 30(3):665-77. PubMed ID: 27113003
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. HLA class I depletion by citric acid, and irradiation of apheresis platelets for transfusion of refractory patients.
    Mirlashari MR, Vetlesen A, Nissen-Meyer LSH, Naper C, Tjønnfjord GE, Njerve IU, Ezligini F, Landmark BF, Meinke S, Sandgren P, Höglund P, Hetland G.
    Transfusion; 2021 Apr; 61(4):1222-1234. PubMed ID: 33580979
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity.
    Petz LD, Garratty G, Calhoun L, Clark BD, Terasaki PI, Gresens C, Gornbein JA, Landaw EM, Smith R, Cecka JM.
    Transfusion; 2000 Dec; 40(12):1446-56. PubMed ID: 11134563
    [Abstract] [Full Text] [Related]

  • 13. Refractory response to platelet transfusion therapy.
    Eisenberg S.
    J Infus Nurs; 2010 Dec; 33(2):89-97. PubMed ID: 20228646
    [Abstract] [Full Text] [Related]

  • 14. Use of HLA- and HPA--matched platelets in alloimmunized patients.
    Kekomäki R.
    Vox Sang; 1998 Dec; 74 Suppl 2():359-63. PubMed ID: 9704468
    [Abstract] [Full Text] [Related]

  • 15. HLA-Mediated Platelet Refractoriness.
    Schmidt AE, Refaai MA, Coppage M.
    Am J Clin Pathol; 2019 Mar 01; 151(4):353-363. PubMed ID: 30285067
    [Abstract] [Full Text] [Related]

  • 16. Recognition and management of antibodies to human platelet antigens in platelet transfusion-refractory patients.
    Vassallo RR.
    Immunohematology; 2009 Mar 01; 25(3):119-24. PubMed ID: 20406018
    [Abstract] [Full Text] [Related]

  • 17. [Prevention of HLA-alloimmunization of recipients of platelet concentrates].
    Kuntz BM, Wollenhaupt HJ, Brüster HT.
    Beitr Infusionsther; 1991 Mar 01; 28():209-12. PubMed ID: 1725621
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.